Shak S - Search Results

1

Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, Kaner RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi I, Shak S, Crystal RG. Harvey BG, et al. Among authors: shak s. J Clin Invest. 1999 Nov;104(9):1245-55. doi: 10.1172/JCI7935. J Clin Invest. 1999. PMID: 10545523 Free PMC article. Clinical Trial.

2

Coarse spray delivery to a localized region of the pulmonary airways for gene therapy.

Cipolla DC, Gonda I, Shak S, Kovesdi I, Crystal R, Sweeney TD. Cipolla DC, et al. Among authors: shak s. Hum Gene Ther. 2000 Jan 20;11(2):361-71. doi: 10.1089/10430340050016085. Hum Gene Ther. 2000. PMID: 10680848

3

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. Hubbard RC, et al. Among authors: shak s. N Engl J Med. 1992 Mar 19;326(12):812-5. doi: 10.1056/NEJM199203193261207. N Engl J Med. 1992. PMID: 1538726 Free article. Clinical Trial. No abstract available.

4

Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.

Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Aitken ML, et al. Among authors: shak s. JAMA. 1992 Apr 8;267(14):1947-51. JAMA. 1992. PMID: 1548827 Clinical Trial.

5

[rhDNase: scientific background, cloning and production].

Shak S. Shak S. Arch Pediatr. 1995 Jul;2(7):666-9. doi: 10.1016/0929-693x(96)81223-1. Arch Pediatr. 1995. PMID: 7663657 Review. French.

6

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M. Ranasinha C, et al. Among authors: shak s. Lancet. 1993 Jul 24;342(8865):199-202. doi: 10.1016/0140-6736(93)92297-7. Lancet. 1993. PMID: 8100928 Clinical Trial.

7

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Cobleigh MA, et al. Among authors: shak s. J Clin Oncol. 1999 Sep;17(9):2639-48. doi: 10.1200/JCO.1999.17.9.2639. J Clin Oncol. 1999. PMID: 10561337 Corrected and republished. Clinical Trial.

8

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.

Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. Woodward WA, et al. Among authors: shak s. JAMA Oncol. 2020 Apr 1;6(4):505-511. doi: 10.1001/jamaoncol.2019.5559. JAMA Oncol. 2020. PMID: 31917424 Free PMC article. Clinical Trial.

9

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Shak S, et al. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188-92. doi: 10.1073/pnas.87.23.9188. Proc Natl Acad Sci U S A. 1990. PMID: 2251263 Free PMC article.

10

Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.

Shak S. Shak S. Chest. 1995 Feb;107(2 Suppl):65S-70S. doi: 10.1378/chest.107.2_supplement.65s. Chest. 1995. PMID: 7842816 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page